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A B S T R A C T
Human papillomavirus (HPV) infection is the most common sexually transmitted infection, especially among young,
sexually active individuals. As persistent infection with oncogenic types may lead to cervical cancer, HPV testing is a use-
ful tool to screen for women at risk for subsequent development of cervical cancer. The aim of the study was to determine
the prevalence of high-risk HPV (hrHPV) infection in different age groups of cytologically selected women from the
Zagreb region, and to evaluate the frequency and results of repeat hrHPV testing. During a one-year study period (No-
vember 2005 to November 2006), a total of 3,440 cervical samples from women attending gynecological services of public
and private health care systems were received. They were tested for 13 hrHPV genotypes by the polymerase chain reaction
based AMPLICOR HPV test (Roche Molecular Systems). The overall prevalence of hrHPV was 34.6%. Most samples were
obtained from women aged 21–30 years (44.2%), followed by the 31–40 (27.6%), 41–50 (15.7%), 51–60 (5.3%) and ³61
(2.4%) age groups. Out of 3,227 cervical samples obtained from women of known age, 4.9% were obtained from the group
of girls younger than 21, in which the highest prevalence of hrHPV (49.4%) was found. A similar prevalence was ob-
served in women aged 21–30 (45.1%). The prevalence gradually decreased with age. During the study period, repeat
hrHPV testing was performed in samples from 66 women at different intervals. Out of 28 women that were hrHPV nega-
tive on initial testing, only five women turned positive on repeat testing. Out of 38 women that were positive on initial
testing, in one-third hrHPV could not be detected on repeat testing. As expected, hrHPV infection was highly prevalent in
female adolescents and young women. Further investigation on repeat hrHPV testing is needed to assess virus clearance
and rate of newly acquired infection.
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Introduction
Human papillomavirus (HPV) infection is the most
common sexually transmitted infection1. Among more
than 100 known HPV genotypes, there are 40 that affect
anogenital mucosa2. According to their potential to in-
crease the risk of cervical cancer, they are divided into
low-risk group, which is usually associated with benign
lesions such as condylomata acuminata, and high-risk
HPV (hrHPV) genotypes, which have a role in cervical
carcinogenesis3. High-risk HPV types are demonstrated
in almost 100% of cervical carcinomas4. The infection is
especially prevalent among sexually active adolescents
and young adults, but usually of short duration in these
age groups5. Only persistent infection, which is more
common in older women, may lead to cervical cancer and
its precursor lesions, cervical intraepithelial neoplasia
2/3 (CIN 2/3). The precise role of HPV in the etiology of
cervical cancer is unknown and the host immune system
is considered to be of crucial importance in HPV clear-
ance or development of persistence after primary in-
fection6,7.
HPV testing has a recognized role in improvement of
cervical-cancer screening programmes, evaluation of wo-
men with unclear or low-grade cytological abnormalities,
and follow-up of patients treated for CIN3,8,9. The only
test currently approved by the U.S. Food and Drug Ad-
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ministration for HPV detection is Hybrid Capture 2 HPV
DNA test (HC2) (Digene Corporation, Gaithersburg, MD,
USA). This signal amplification assay detects 13 high-
-risk (16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59 and 68)
and five low-risk (6, 11, 42, 43 and 44) HPV types. Al-
though evaluation of its laboratory performance has con-
firmed its reliability and reproducibility, several recent
studies showed a significant analytical inaccuracy, mainly
due to the cross-reactivity of its high-risk probe cock-
tail10–12. In 2003, a newly developed polymerase chain re-
action based AMPLICOR HPV test (F. Hoffmann-La
Roche Ltd., Basel, Switzerland) was marketed. This tar-
get amplification test detects the same 13 hrHPV types
as HC2 assay, with simultaneous detection of human
b-globin gene, which allows assessment of cellular ade-
quacy, extraction and amplification of each processed
specimen. Some recent studies demonstrated the HC2
assay and AMPLICOR HPV test to give comparable re-
sults, both being suitable for routine use13,14. In a recent
study, the AMPLICOR HPV test demonstrated even
higher analytical sensitivity and specificity13. While the
higher analytical specificity of AMPLICOR HPV in com-
parison to that of HC2 can be considered clinically bene-
ficial, the clinical importance of the higher analytical
sensitivity of AMPLICOR HPV is still a matter for exten-
sive professional discussion13,15.
The aim of the study was to determine the prevalence
of hrHPV infection in different age groups of women
from the Zagreb region using AMPLICOR HPV test, and
to evaluate the frequency and results of repeat hrHPV
testing in the same population.
Materials and Methods
Patients and clinical specimens
During the one-year study period (November 2005 to
November 2006), a total of 3,440 cervical cell specimens
for hrHPV testing were received at the Laboratory of
Molecular Microbiology, Zagreb Institute of Public Health.
The specimens were obtained from cytologically selected
women attending gynecological services of public and
private health care systems in the Zagreb region. The
median age of the women was 31 (range, 15–73) years.
For 213 specimens no data on the patients’ age were
available. Cervical samples were collected by 46 gynecol-
ogists using Cervex-Brush (Rovers Medical Devices). Up-
on sampling, the brush was washed in a ThinPrep vial
containing PreservCyt solution (Cytyc Corporation, Box-
borough, MA, USA). During the study period, repeat
hrHPV testing was performed in samples from 66 wo-
men at different time intervals. The indication for repeat
testing was clinical evaluation of the patients.
Specimen preparation
HPV DNA was isolated from the PreservCyt solution
using AmpliLute Liquid Media Extraction kit (AMPLI-
COR HPV test, Roche Molecular Systems) according to
the manufacturer’s instructions. Briefly, HPV DNA was
released by lysing cervical cells under denaturing condi-
tions at elevated temperatures in the presence of pro-
teinase K, chaotropic agent and detergent, isolated and
purified over columns with silica-based membrane using
vacuum pressure, and eluted with elution reagent. Dur-
ing the procedure, the human b-globin gene was concur-
rently isolated, allowing assessment of cellular adequacy,
extraction and amplification of each processed specimen.
Amplification
Polymerase chain reaction (PCR) based AMPLICOR
HPV test (Roche Molecular Systems) is designated to
amplify HPV DNA from 13 high-risk genotypes (16, 18,
31, 33, 35, 39, 45, 51, 52, 56, 58, 59 and 68). The test am-
plifies 165 bp long nucleotide sequence within the poly-
morphic L1 region of the HPV genome with a master mix
containing biotin labeled primers. An additional primer
pair is added to allow simultaneous amplification of the
human b-globin gene (268 bp amplicon). PCR was per-
formed with a final reaction volume of 100 mL, contain-
ing 50 mL of AMPLICOR HPV master mix and 50 mL of
isolated DNA, on GeneAmp PCR System 9700 with gold
block (Applied Biosystems, Foster City, CA, USA) using
AMPLICOR defined parameters: 2 min at 50 °C and 9
min at 95 °C, followed by 40 cycles of: 30 s at 95 °C, 45 s at
54 °C and 30 s at 72 °C, with a final extension at 72 °C for
no longer than 1 h.
Hybridization and detection
After amplification, the amplicons were chemically
denatured to form single-stranded DNA. Two separate
96-microwell plates, one coated with HPV high-risk probes
and the other with b-globin specific oligonucleotide prob-
es, were used for HPV and b-globin detection. After add-
ing of AMPLICOR hybridization buffer and denatured
amplicons to appropriate wells of both detection plates,
hybridization reaction occurred. Following hybridization
and washing procedures, bound hybrids were detected
with a biotin avidin-horseradish peroxidase assay. The
absorbance at 450 nm was measured immediately using
an automated microwell plate reader (Anthos 2010,
ASYS Hitech, BIOCHROM Group, Great Britain). Ac-
cording to AMPLICOR instructions, HPV absorbance
reading of ³0.20, accompanied with any value of b-globin
result, was considered positive for the presence of hrHPV.
HPV result of <0.20 and b-globin result of ³0.20 was con-
sidered negative for the presence of hrHPV. Test result
could not be interpreted if both (HPV and b-globin)
absorbance values were <0.20. HPV DNA, if present,
could not be detected because of inadequate cell content
of specimen or inadequate extraction or amplification
procedure. In that case, another aliquot of original speci-
men was retested and, if the same result appeared, new
specimen collection was recommended.
Statistical methods
Proportions were compared by the c2-test. A p value
<0.01 was considered statistically significant. The 95%
confidence interval for a proportion was calculated ac-
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cording the Wilson procedure with a correction for con-
tinuity16. The decrease of hrHPV prevalence with age
was estimated by the c2-goodness of fit to rectangular
distribution using STATISTICA 7.1 (StatSoft Inc., Tulsa,
OK, USA).
Results
Results of this study conducted during the one-year
period in 3,440 cervical samples tested for the presence
of 13 hrHPV types by AMPLICOR HPV test showed the
overall hrHPV prevalence to be 34.6%. Out of 3,227 cer-
vical specimens from women of known age, hrHPV was
detected in 1,120 (34.7%) samples. In four (0.1%) sam-
ples, HPV test results could not be interpreted. Out of
213 cervical samples from women with no age data avail-
able, hrHPV was detected in 70 (32.9%) samples (c2=
0.24, p>0.01).
Out of 3,227 cervical samples obtained from women of
known age, 158 (4.9%) were obtained from the group of
girls younger than 21, in which the highest prevalence of
hrHPV (49.4%) was recorded. Most cervical specimens
were obtained from women aged 21–30 (1,425 samples,
44.2%); in this group hrHPV was detected in 642 (45.1%)
patients. The prevalence of hrHPV gradually decreased
with age (c2=1,531.3, df=5, p<0.01). In the 31–40 age
group (27.6% of study patients), the recorded prevalence
was 28.9%, followed by 19.3% in the 41–50 age group and
13.5% in the 51–60 age group. In women older than 60,
the prevalence of hrHPV was 28.9% (Table 1). There was
a statistically significant difference in the distribution of
hrHPV genotypes according to age groups (c2=183.96,
df=5, p<0.01), which was due to the higher prevalence of
hrHPV in younger women (£30 years).
Out of 3,440 cervical samples tested for hrHPV, 1,168
(34%) of samples were diagnosed as atypical squamous
cells of undetermined significance (ASCUS), 468 (13.6%)
of samples were diagnosed as dysplasia levis or CIN 1,
152 (4.4%) of samples were diagnosed as CIN 2 (n=107),
CIN 3 (n=43) or carcinoma in situ (n=2), and for 1,652
(48%) of samples the informations regarding cervical ab-
normalities were not available. In the ASCUS group
hrHPV was detected in 432 (37%) patients. The preva-
lence of hrHPV increased with the severity of cervical
lesions. In the CIN 1 group hrHPV was detected in 201
(43%) and in the CIN 2/3 group in 111 (73%) patients
(c2=158.1, p<0.01).
During the study period, repeat hrHPV testing was
performed in samples from 66 women at different inter-
vals. Out of 28 women found to be hrHPV negative on
initial testing, only five women turned positive on repeat
testing. Six women underwent retesting within three
months of initial testing, all of them being negative for
hrHPV again. Of twelve women that underwent re-test-
ing within 3–6 months, hrHPV was detected in three
cases. In seven women, repeat testing was performed
within 6–9 months, one of them being positive for hr-
HPV. Three women underwent retesting within 9–12
months, with hrHPV detected in one case.
On repeat testing, hrHPV could not be detected in
one third of 38 women found hrHPV positive on initial
testing. Repeat testing within three months was per-
formed in 11 women, two of them negative; within 3–6
months in 15 women, six of them negative; within 6–9
months in nine women, four of them negative; and with-
in 9–12 months in three women, all of them positive.
Discussion and Conclusion
The present study assessed the prevalence of hrHPV
types among cytologically selected women from a large,
well-defined region in Croatia, tested during the one-
-year period at Zagreb Institute of Public Health. In
3,440 tested women with cytologically abnormal smears,
the prevalence of hrHPV was 34.6%.
The prevalence of hrHPV is known to decrease with
age, from 20% among women aged 20–30 to 5% in women
aged >30, as estimated in previous studies in pregnant
and non-pregnant women with cytomorphologically nor-
mal cervical smears17–19. Although the prevalence of
hrHPV is considerably higher among women with cyto-
logically abnormal smears, a higher rate of hrHPV is still
recorded in women aged <30 than in those from older
age groups irrespective of the grade of cytological abnor-
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TABLE 1
RESULTS OF CERVICAL SAMPLES TESTED FOR 13 HIGH-RISK HPV GENOTYPES BY AMPLICOR
HPV TEST ACCORDING TO PATIENTS AGE
Age (years)
Total
n=3,227
NTa Positiveb
n=4 % n=1,120 % 95%CIc
£20 158 0 0 78 49.4 41.4–57.4
21–30 1,425 2 0.1 642 45.1 42.5–47.7
31–40 889 2 0.2 257 28.9 26.0–32.0
41–50 508 0 0 98 19.3 16.0–23.1
51–60 171 0 0 23 13.5 8.9–19.7
³61 76 0 0 22 28.9 19.4–40.7
HPV – human papillomavirus, aNT – not possible to interpret, bc2=183.96, df=5, p<0.01, cCI – confidence interval
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mality. A recent study of the distribution of HPV types in
ThinPrep Papanicolaou (Pap) tests classified according
to the »Bethesda 2001 terminology« in correlation with
patient age detected one or more of 13 hrHPV types in
53% of samples diagnosed as atypical squamous cells of
undetermined significance (59% of patients aged <30
and 45.5% of patients aged 30), 55.5% of samples diag-
nosed as low-grade squamous intraepithelial lesion (60%
of patients aged <30 and 44% of patients aged 30), 80%
of samples in which the high-grade squamous intraepi-
thelial lesion could not be ruled out; and 87.5% of sam-
ples diagnosed as high-grade squamous intraepithelial
lesion20. In the present retrospective study, most cervical
specimens were obtained from women aged 21–30 (44.2%),
in which group hrHPV was detected in 45.1% of patients.
Limitations of the study included the unavailability of
cytological, clinical and epidemiological data for all pa-
tients, and involvement of a great number of gynecolo-
gists and cytologists, which resulted in variable classifi-
cation of cervical abnormality. Additional prospective
investigation of samples cytologically diagnosed accord-
ing to the »Bethesda 2001 guidelines« is needed.
As expected, hrHPV infection was found to be highly
prevalent in female adolescents and young women from
the Zagreb region. Similar findings were recorded in a
study conducted in 1998 and 1999 in Croatia, when 466
women with minor and moderate cervical abnormalities
were tested. The prevalence of hrHPV was found to be
66% in women aged <20, 57% in women aged 20–29, and
65% in women aged 30–3921. In this study, the decline of
hrHPV prevalence with age was less pronounced because
of the small number of subjects, especially those over age
50. In another study published in 2001, assessing the
prevalence of HPV in cervical specimens obtained from
1,874 women with abnormal Pap smears collected during
the 1996–1998 period, the HPV positivity rate declined
with age22. In a more recent study, the same authors
demonstrated the presence of HPV in cervical samples to
significantly increase with the severity of cervical le-
sions23. The same was observed in the present study
which is valuable because of the great number of women
included, yielding relevant epidemiological data for this
geographical region. However, properly designed, target
studies are necessary to overcome the shortcomings of
the present, retrospective study.
During the one-year study period, only 66 women
were tested on multiple occasions, which cannot be con-
sidered a relevant sample, therefore further investiga-
tion with repeat hrHPV testing is needed to assess virus
clearance and rate of newly acquired infection in correla-
tion with patient age and cytological diagnosis.
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INFEKCIJA GENITALNIM HUMANIM PAPILOMAVIRUSIMA U @ENA
SA ZAGREBA^KOG PODRU^JA
S A @ E T A K
Infekcija humanim papilomavirusima (HPV) naj~e{}a je spolno prenosiva bolest, poglavito u mladih, seksualno ak-
tivnih osoba. Kako ustrajna infekcija mo`e dovesti do raka vrata maternice, testiranje na HPV je korisno sredstvo u
probiranju `ena koje su pod pove}anim rizikom od razvoja karcinoma vrata maternice. Cilj ovoga rada bio je utvrditi
prevalenciju infekcije HPV visokog rizika (hrHPV, engl. high risk HPV) u razli~itim dobnim skupinama citolo{ki odab-
ranih `ena sa zagreba~kog podru~ja, te analizirati u~estalost i rezultate ponovljenih testiranja na hrHPV. U promat-
ranom jednogodi{njem razdoblju (studeni 2005. do studeni 2006.) ukupno je zaprimljeno 3.440 uzoraka obrisaka vrata
maternice `ena iz ginekolo{kih ambulanata domova zdravlja i privatnih ginekolo{kih ordinacija. Uzorci su testirani na
prisutnost 13 genotipova hrHPV testom AMPLICOR HPV (Roche Molecular Systems), koji se temelji na lan~anoj re-
akciji polimerazom. Ukupna prevalencija hrHPV iznosila je 34,6%. Ve}ina uzoraka zaprimljena je od `ena u dobnoj
skupini od 21–30 godina (44,2%), a slijedile su dobne skupine `ena od 31–40 (27,6%), 41–50 (15,7%), 51–60 (5,3%) i ³61
godine (2,4%). Od ukupno 3.227 obrisaka vrata maternice zaprimljenih od `ena poznate dobi 4,9% je otpadalo na po-
pulaciju djevojaka mla|ih od 21 godine. U toj dobnoj skupini utvr|ena je najve}a prevalencija infekcije hrHPV (49,4%).
Sli~na prevalencija uo~ena je u `ena dobne skupine od 21–30 godina (45,1%). U starijim dobnim skupinama preva-
lencija se postupno smanjivala. U promatranom razdoblju testiranje na hrHPV ponovljeno je u razli~itim vremenskim
razmacima na uzorcima dobivenim od 66 `ena. Od 28 `ena koje su na prvom testiranju bile negativne samo ih je pet bilo
pozitivno na ponovnom testiranju. Od 38 `ena koje su na prvom testiranju bile pozitivne u jedne tre}ine se hrHPV se
nije mogao utvrditi kod ponovnog testiranja. Kako se je o~ekivalo, infekcija hrHPV naju~estalija je u adolescentica i
mladih `ena. Potrebna su daljnja istra`ivanja o ponavljanim hrHPV testiranjima kako bi se mogla procijeniti stopa
i{~ezavanja virusa i stopa novo ste~enih infekcija.
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